2025 H2 -tulosraportti
16 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 8 | - | - | ||
| 9 | - | - | ||
| 1 040 | - | - | ||
| 108 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sitten · MuokattuI think it's easy to underestimate how many doses are actually used per patient in targeted alpha therapy when trying to estimate Thor's potential. It's easy to think that 1 patient = 1 dose of isotope. In practice, this is often not the case. Many alpha therapies are given in several treatment cycles, typically 3–6 rounds where the patient receives a new dose each time. This means that one patient can practically use around 4 doses, sometimes more. This has quite significant implications when looking at AlphaOne's capacity. The factory is designed for approximately 21,000 doses per year when fully up and running. If one assumes 1 dose per patient, that corresponds to 21,000 patients. But if a treatment in reality uses around 4 doses per patient, it means that the capacity rather corresponds to around 5,000 patients. With the prices Thor has already communicated in contracts – around 15,000–16,000 kroner per dose – full capacity at AlphaOne yields approximately 320 million kroner in annual revenue. My point is that the demand for isotopes can become much greater than one intuitively thinks, precisely because treatments often require multiple doses per patient. If one or more drugs succeed in clinical trials and move towards approval, the need for isotopes can grow rapidly and become absolutely enormous. Then one can also quickly find oneself in a situation where AlphaOne alone is not enough, and where further expansion of capacity becomes relevant – and this quickly. Thor says they believe the first medicines may first receive approvals in 2028. Before that, they sell for research, testing, etc. 2028-2029 is 2-3 years away for you. What an incredibly exciting stock this actually is. Yes, there is of course a lot of risk regarding production, ramp up, competitors, price/earnings per dose in the future (what they can actually charge), margins, other cancer medicines/methods, etc. Things can happen, but if they succeed and medicines succeed. Oh my goodness 💥- ·1 päivä sittenHeads up, heads up. Someone is quietly accumulating shares in Thor Medical now.
·21 t sittenI haven't checked daily, is there a big change on the topp50?
·20 t sitten · MuokattuNo, no big changes this week. Will be exciting to see on Monday. 
·1 päivä sittenjust before I throw in the buffer account
·1 päivä sittenI must say that after yesterday's rise, Thor is holding up incredibly well. It wouldn't surprise me if we end up in positive territory today too 🌞Thor will be my future. Happy weekend everyone🍀
·1 päivä sittenCompletely agree. A lot of turmoil in the market and it holds up well. Even with a marginal dilution it stands steady.·1 päivä sittenInsider trading if you ask me. Bull flag 🇳🇴 Thor- ·1 päivä sittenKI : Gemini said For those of you holding shares in Thor Medical, this is fundamentally a neutral to slightly positive message, even though it involves a small dilution. Here are the three most important points you should note: 1. Minimal dilution When the company issues new shares, your ownership stake technically becomes slightly smaller because the "pie" is divided into more pieces. But in this case, the number of shares is so low relative to the total that it is barely noticeable in the share price: Before: 358,411,748 shares (approximate figure based on the previous announcement). Now: 359,782,299 shares. Effect: We are talking about an increase of around 0.38%. For most small shareholders, this has no practical significance for the value of their portfolio. 2. Employees "lock themselves in" This is perhaps the most important point. The message states that employees/management have chosen to exercise their options. They have thus used their own money to buy shares in the company they work for. This is a sign of health. Employees who are on the inside and see the daily progress at Herøya would hardly have exercised options if they believed the share price would fall going forward. 3. The company receives some fresh capital Although the main purpose is an incentive for the employees, those who exercise options must pay an agreed price (exercise price) to the company. This provides Thor Medical with a small sum of cash that somewhat strengthens its liquidity.
1 päivä sitten1 päivä sitten😂😂·1 päivä sitten · Muokattu5℅ of what then? To invest more for me is not logical. I find Thor interesting. What are you insinuating? 😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
16 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · MuokattuI think it's easy to underestimate how many doses are actually used per patient in targeted alpha therapy when trying to estimate Thor's potential. It's easy to think that 1 patient = 1 dose of isotope. In practice, this is often not the case. Many alpha therapies are given in several treatment cycles, typically 3–6 rounds where the patient receives a new dose each time. This means that one patient can practically use around 4 doses, sometimes more. This has quite significant implications when looking at AlphaOne's capacity. The factory is designed for approximately 21,000 doses per year when fully up and running. If one assumes 1 dose per patient, that corresponds to 21,000 patients. But if a treatment in reality uses around 4 doses per patient, it means that the capacity rather corresponds to around 5,000 patients. With the prices Thor has already communicated in contracts – around 15,000–16,000 kroner per dose – full capacity at AlphaOne yields approximately 320 million kroner in annual revenue. My point is that the demand for isotopes can become much greater than one intuitively thinks, precisely because treatments often require multiple doses per patient. If one or more drugs succeed in clinical trials and move towards approval, the need for isotopes can grow rapidly and become absolutely enormous. Then one can also quickly find oneself in a situation where AlphaOne alone is not enough, and where further expansion of capacity becomes relevant – and this quickly. Thor says they believe the first medicines may first receive approvals in 2028. Before that, they sell for research, testing, etc. 2028-2029 is 2-3 years away for you. What an incredibly exciting stock this actually is. Yes, there is of course a lot of risk regarding production, ramp up, competitors, price/earnings per dose in the future (what they can actually charge), margins, other cancer medicines/methods, etc. Things can happen, but if they succeed and medicines succeed. Oh my goodness 💥
- ·1 päivä sittenHeads up, heads up. Someone is quietly accumulating shares in Thor Medical now.·21 t sittenI haven't checked daily, is there a big change on the topp50?·20 t sitten · MuokattuNo, no big changes this week. Will be exciting to see on Monday.
- ·1 päivä sittenjust before I throw in the buffer account
- ·1 päivä sittenI must say that after yesterday's rise, Thor is holding up incredibly well. It wouldn't surprise me if we end up in positive territory today too 🌞Thor will be my future. Happy weekend everyone🍀·1 päivä sittenCompletely agree. A lot of turmoil in the market and it holds up well. Even with a marginal dilution it stands steady.·1 päivä sittenInsider trading if you ask me. Bull flag 🇳🇴 Thor
- ·1 päivä sittenKI : Gemini said For those of you holding shares in Thor Medical, this is fundamentally a neutral to slightly positive message, even though it involves a small dilution. Here are the three most important points you should note: 1. Minimal dilution When the company issues new shares, your ownership stake technically becomes slightly smaller because the "pie" is divided into more pieces. But in this case, the number of shares is so low relative to the total that it is barely noticeable in the share price: Before: 358,411,748 shares (approximate figure based on the previous announcement). Now: 359,782,299 shares. Effect: We are talking about an increase of around 0.38%. For most small shareholders, this has no practical significance for the value of their portfolio. 2. Employees "lock themselves in" This is perhaps the most important point. The message states that employees/management have chosen to exercise their options. They have thus used their own money to buy shares in the company they work for. This is a sign of health. Employees who are on the inside and see the daily progress at Herøya would hardly have exercised options if they believed the share price would fall going forward. 3. The company receives some fresh capital Although the main purpose is an incentive for the employees, those who exercise options must pay an agreed price (exercise price) to the company. This provides Thor Medical with a small sum of cash that somewhat strengthens its liquidity.1 päivä sitten1 päivä sitten😂😂·1 päivä sitten · Muokattu5℅ of what then? To invest more for me is not logical. I find Thor interesting. What are you insinuating? 😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 8 | - | - | ||
| 9 | - | - | ||
| 1 040 | - | - | ||
| 108 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
16 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · MuokattuI think it's easy to underestimate how many doses are actually used per patient in targeted alpha therapy when trying to estimate Thor's potential. It's easy to think that 1 patient = 1 dose of isotope. In practice, this is often not the case. Many alpha therapies are given in several treatment cycles, typically 3–6 rounds where the patient receives a new dose each time. This means that one patient can practically use around 4 doses, sometimes more. This has quite significant implications when looking at AlphaOne's capacity. The factory is designed for approximately 21,000 doses per year when fully up and running. If one assumes 1 dose per patient, that corresponds to 21,000 patients. But if a treatment in reality uses around 4 doses per patient, it means that the capacity rather corresponds to around 5,000 patients. With the prices Thor has already communicated in contracts – around 15,000–16,000 kroner per dose – full capacity at AlphaOne yields approximately 320 million kroner in annual revenue. My point is that the demand for isotopes can become much greater than one intuitively thinks, precisely because treatments often require multiple doses per patient. If one or more drugs succeed in clinical trials and move towards approval, the need for isotopes can grow rapidly and become absolutely enormous. Then one can also quickly find oneself in a situation where AlphaOne alone is not enough, and where further expansion of capacity becomes relevant – and this quickly. Thor says they believe the first medicines may first receive approvals in 2028. Before that, they sell for research, testing, etc. 2028-2029 is 2-3 years away for you. What an incredibly exciting stock this actually is. Yes, there is of course a lot of risk regarding production, ramp up, competitors, price/earnings per dose in the future (what they can actually charge), margins, other cancer medicines/methods, etc. Things can happen, but if they succeed and medicines succeed. Oh my goodness 💥
- ·1 päivä sittenHeads up, heads up. Someone is quietly accumulating shares in Thor Medical now.·21 t sittenI haven't checked daily, is there a big change on the topp50?·20 t sitten · MuokattuNo, no big changes this week. Will be exciting to see on Monday.
- ·1 päivä sittenjust before I throw in the buffer account
- ·1 päivä sittenI must say that after yesterday's rise, Thor is holding up incredibly well. It wouldn't surprise me if we end up in positive territory today too 🌞Thor will be my future. Happy weekend everyone🍀·1 päivä sittenCompletely agree. A lot of turmoil in the market and it holds up well. Even with a marginal dilution it stands steady.·1 päivä sittenInsider trading if you ask me. Bull flag 🇳🇴 Thor
- ·1 päivä sittenKI : Gemini said For those of you holding shares in Thor Medical, this is fundamentally a neutral to slightly positive message, even though it involves a small dilution. Here are the three most important points you should note: 1. Minimal dilution When the company issues new shares, your ownership stake technically becomes slightly smaller because the "pie" is divided into more pieces. But in this case, the number of shares is so low relative to the total that it is barely noticeable in the share price: Before: 358,411,748 shares (approximate figure based on the previous announcement). Now: 359,782,299 shares. Effect: We are talking about an increase of around 0.38%. For most small shareholders, this has no practical significance for the value of their portfolio. 2. Employees "lock themselves in" This is perhaps the most important point. The message states that employees/management have chosen to exercise their options. They have thus used their own money to buy shares in the company they work for. This is a sign of health. Employees who are on the inside and see the daily progress at Herøya would hardly have exercised options if they believed the share price would fall going forward. 3. The company receives some fresh capital Although the main purpose is an incentive for the employees, those who exercise options must pay an agreed price (exercise price) to the company. This provides Thor Medical with a small sum of cash that somewhat strengthens its liquidity.1 päivä sitten1 päivä sitten😂😂·1 päivä sitten · Muokattu5℅ of what then? To invest more for me is not logical. I find Thor interesting. What are you insinuating? 😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 8 | - | - | ||
| 9 | - | - | ||
| 1 040 | - | - | ||
| 108 | - | - |
Välittäjätilasto
Dataa ei löytynyt